Peptides for Muscle Growth: What the Evidence Shows

When people talk about peptides for muscle growth, they almost always mean peptides that make the body release more growth hormone. The best known are ipamorelin, CJC-1295, sermorelin, tesamorelin, GHRP-2, GHRP-6 and hexarelin. Together they are called growth hormone secretagogues, and the biology is covered in depth in Growth Hormone Secretagogues.

The idea behind them is a chain of reasoning: growth hormone helps children grow, growth hormone raises IGF-1, IGF-1 can stimulate muscle cells, so raising growth hormone should build muscle. Each link sounds plausible. The question this guide asks is which links have actually been tested in people, and with what result.

The short answer is that the chain breaks at the end. Growth hormone peptides do raise hormone levels in people. Growth hormone itself, given in randomised trials, adds lean body mass. But in healthy adults that extra lean mass has not translated into reliable gains in strength or performance [1], and no randomised trial has measured muscle outcomes for the popular research peptides at all.

A smaller group of online claims concerns the myostatin pathway, a separate brake on muscle growth. That research is real, but the drugs involved are large antibodies and engineered proteins in clinical development, not the short peptides sold online (see section 6). This guide describes evidence and regulatory status only. It gives no doses or instructions, and decisions about any treatment belong to a licensed clinician.

Growth hormone is released by the pituitary gland in pulses, mostly during sleep. Two signals push it up and one holds it back. Growth hormone-releasing hormone (GHRH) from the hypothalamus stimulates release, ghrelin from the stomach amplifies it, and somatostatin brakes it. Growth hormone then prompts the liver to make IGF-1, which carries many of its effects and feeds back to slow further release.

Muscle-marketed peptides copy one of the two “go” signals:

• GHRH analogues act on the GHRH receptor. Sermorelin is the first 29 amino acids of human GHRH. Tesamorelin is a stabilised GHRH analogue. CJC-1295 was engineered to last much longer: in healthy adults, a single injection raised growth hormone and IGF-1 for days, with an estimated half-life of roughly a week [3].
• Ghrelin mimetics, also called growth hormone-releasing peptides (GHRPs), act on the ghrelin receptor (GHS-R1a). These include GHRP-2, GHRP-6, hexarelin and ipamorelin. Ipamorelin was developed to be more selective for growth hormone than older GHRPs, which also raise cortisol and prolactin.

Because the two receptor routes are different, the two classes can add together, which is the rationale behind the widely promoted “CJC-1295 and ipamorelin” combination. Synergy on hormone levels, however, has only been shown for the natural hormones in short laboratory studies, as explained in Growth Hormone Secretagogues. It says nothing about muscle.

Secretagogues also keep some of the body's own controls in place. IGF-1 feedback and somatostatin still limit release, so the effect differs from injecting growth hormone directly. That difference is often marketed as a safety advantage, but it has not been tested as one in long-term trials. For how peptides act on cell-surface receptors in general, see Peptide Receptors.

Because the popular peptides have not been tested for muscle, the closest evidence comes from trials that gave growth hormone itself, or a ghrelin mimetic, and measured body composition and strength.

• Healthy young adults. A 2008 systematic review in the Annals of Internal Medicine pooled randomised trials in physically fit people aged 13 to 45 (303 participants given growth hormone). Lean body mass rose by about 2.1 kg compared with controls, but strength and exercise capacity did not appear to improve. Soft-tissue swelling and fatigue were more common with growth hormone, and the authors concluded that claims of better performance are not supported [1].
• Growth hormone plus weight training. In a 12-week randomised trial of 16 young men doing identical resistance training, fat-free mass rose more with growth hormone than with placebo, but muscle protein synthesis, limb size and strength did not. The researchers concluded the extra lean mass was probably tissue other than skeletal muscle [2].
• Recreational athletes. A randomised trial of 96 recreationally trained adults found that growth hormone increased lean body mass mainly through extracellular water. Sprint capacity rose modestly, but strength, power and endurance did not change, and the sprint effect was gone six weeks after stopping [6].
• Healthy older adults. A 2007 systematic review of trials in people with an average age of 69 found about 2 kg more lean mass and 2 kg less fat, with more swelling, joint pain, carpal tunnel syndrome and breast enlargement in men, and a trend towards diabetes. The authors concluded growth hormone could not be recommended as an anti-ageing therapy [5].
• An oral ghrelin mimetic. In a two-year trial in 65 healthy older adults, ibutamoren (MK-677, a small molecule rather than a peptide) raised growth hormone and IGF-1 to young-adult levels and increased fat-free mass, but strength and function did not change. Fasting glucose rose and insulin sensitivity fell [7].
• Muscle wasting in cancer. Anamorelin, a ghrelin-receptor drug, increased lean body mass in two phase 3 trials in 979 people with advanced lung cancer, but handgrip strength did not improve [8].

The pattern is consistent across populations: more lean mass on a scan, without a matching gain in strength. Part of the reason is that “lean body mass” includes water, connective tissue and organs, not just contractile muscle. For how to judge outcomes like these, see Statistical vs Clinical Significance.

For the specific peptides promoted to build muscle, the human evidence looks like this, as of 17 October 2026:

Tesamorelin is the only one with an approved use in the U.S., and its label is precise about what that covers: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The label adds that it is not indicated for weight loss, that long-term cardiovascular safety has not been established, and that the effects of prolonged IGF-1 elevation are unknown [4]. Muscle growth is not part of the approval.

Ipamorelin reached phase 2 trials, but for a gut problem, not muscle. In a randomised trial in 114 people after bowel surgery, it did not shorten the time to tolerating solid food compared with placebo [9].

CJC-1295 and ipamorelin together is one of the most searched combinations. A PubMed search on 17 October 2026 for both names returned review articles and a laboratory testing paper, but no clinical trial of the combination. Claims about it rest on mechanism and anecdote. For why combining unapproved peptides adds uncertainty rather than removing it, see Peptide Stacks, and for direct comparisons see CJC-1295 vs Ipamorelin and GHRP-2 vs GHRP-6.

It can seem strange that compounds discussed so widely have never been tested for the use they are known for. There are several reasons.

• No approvable indication. Drug companies run large trials to win approval for a medical condition. Building muscle in healthy people is not a disease, and regulators would not approve a drug for it. The companies that developed these peptides aimed at growth hormone deficiency, HIV-related fat, gut motility or diagnostic testing instead.
• Development went elsewhere or stalled. Where these peptides were tested in patients, it was for other problems, and results were often disappointing, as with ipamorelin after bowel surgery [9]. None is in late-stage development for muscle, so no sponsor is paying for such trials.
• The growth hormone results were discouraging. If growth hormone itself does not reliably improve strength in healthy adults [1][2], a peptide that raises growth hormone less directly is unlikely to do better, which removes the scientific case for an expensive trial.
• Ethics and sport. Trials giving performance-enhancing substances to healthy people are hard to justify, and all of these compounds are banned in sport.

The result is an evidence gap that marketing fills with mechanism diagrams, animal studies and personal reports. Those are the weakest kinds of evidence for answering whether something works in people, as explained in Human vs Preclinical Research and Understanding Evidence Levels. Because no muscle-building trials exist, there is also no evidence-based human dose for this purpose, and any figure circulating online is not derived from controlled studies.

Myostatin is a protein that limits muscle growth. In 1997, mice bred without the myostatin gene were found to have individual muscles weighing two to three times more than normal [11]. In 2004, a child born with mutations disabling both copies of the human gene was reported to have greatly enlarged muscles [12]. Those findings started a search for drugs that block myostatin or its receptor.

Human trials have so far been in muscle diseases and sarcopenia, with mixed results:

• MYO-029, an antibody against myostatin, was tested in 116 adults with muscular dystrophy. It showed no improvement in strength or function, although the trial was mainly designed to check safety [13].
• ACE-031, a decoy receptor protein, showed trends towards more lean mass in boys with Duchenne muscular dystrophy, but the trial was stopped early because of nosebleeds and small dilated blood vessels [14].
• Bimagrumab, an antibody that blocks the activin type II receptor, increased thigh muscle volume in a small 24-week trial of 40 older adults with sarcopenia, and improved walking in those who were slowest at the start [15].

Two points matter for readers. First, these are large antibodies and engineered proteins given in supervised trials, not short peptides. Products sold online as “follistatin” or “myostatin-blocking peptides” have not been tested in these trials, and their identity is not assured. Second, none of these drugs was approved for muscle growth as of 17 October 2026. The research shows that the pathway can be targeted, not that any available product does so safely.

The known and suspected risks of raising growth hormone come mostly from trials of growth hormone, tesamorelin and ibutamoren:

• Blood sugar. Growth hormone opposes insulin. Tesamorelin users had a higher rate of diabetes-range HbA1c than placebo users (5% versus 1%) [4], and ibutamoren reduced insulin sensitivity [7].
• Swelling, joint pain and carpal tunnel syndrome, seen more often with growth hormone in healthy older adults [5].
• IGF-1 and cancer. Because IGF-1 promotes cell growth, the tesamorelin label excludes people with active cancer and calls the effects of prolonged IGF-1 elevation unknown [4].
• Product quality. FDA has placed GHRP-2, GHRP-6 and ipamorelin in its category of bulk substances that may present significant safety risks in compounding, citing risks of immune reactions and impurities. It notes a death in a study where ipamorelin was given intravenously, though without establishing cause, and serious adverse events including increased heart rate and a vasodilatory reaction with CJC-1295 [10].

Are peptides safer than steroids? The honest answer is that the comparison cannot be made on current evidence. Anabolic steroids clearly build muscle: in a randomised trial, high-dose testosterone increased muscle size and strength in healthy men, especially with training [16]. Their harms are also well documented, including cardiovascular, psychiatric, liver and hormonal effects, and an increased risk of death among users [17]. Growth hormone peptides have far weaker evidence of benefit and almost no long-term safety data in healthy users. “Less studied” is not the same as “safer”. The differences in chemistry and mechanism are explained in Peptides vs Steroids, and wider safety questions in Are Peptides Safe? and Peptide Impurities. Whether any treatment is appropriate is a decision for a licensed clinician.

The World Anti-Doping Agency (WADA) 2026 Prohibited List bans all of the substances in this guide at all times, in and out of competition [18]:

• Class S2.2.4, growth hormone releasing factors, names GHRH analogues including CJC-1295, sermorelin and tesamorelin; secretagogues including ipamorelin, ibutamoren and anamorelin; and GH-releasing peptides including GHRP-2, GHRP-6 and examorelin (hexarelin).
• Class S2.2.3 covers growth hormone, its analogues and fragments, and S2.3 covers growth factors including IGF-1 and its analogues.
• Class S4.3 covers agents preventing activin receptor IIB activation, which names myostatin inhibitors, myostatin-binding proteins such as follistatin, ACE-031 and bimagrumab.

The list also bans substances with a similar chemical structure or biological effect, so an unnamed analogue is not automatically permitted. Athletes with a genuine medical need use the therapeutic use exemption process. See WADA Peptide Rules and Peptides and Athletes.

Do peptides help build muscle?

No peptide has been shown in a randomised trial to build muscle or strength in healthy people. Growth hormone, which these peptides release, increased lean mass in trials but did not reliably improve strength [1][2].

How do peptides work for muscle growth?

The popular ones make the pituitary release more growth hormone, either by mimicking GHRH (CJC-1295, sermorelin, tesamorelin) or ghrelin (ipamorelin, GHRP-2, GHRP-6, hexarelin). Growth hormone raises IGF-1, which in theory supports muscle growth. The theory has not been confirmed by muscle outcomes in trials of these peptides.

What are the benefits of ipamorelin?

Ipamorelin reliably raises growth hormone in short studies. Its only published phase 2 trial, in recovery after bowel surgery, did not find a benefit over placebo [9]. Claimed benefits for muscle, fat loss, sleep or recovery have not been tested in controlled human trials, and it is not an approved medicine.

Does CJC-1295 with ipamorelin work better than either alone?

The combination targets two different receptors, so it may raise growth hormone more than either alone. No clinical trial of the combination has been published, so there is no evidence that it builds muscle or is safe for repeated use.

Are peptides safer than steroids?

That cannot be stated on current evidence. Steroids have proven muscle effects and well-documented harms [16][17]. Growth hormone peptides have little evidence of muscle benefit and very little long-term safety data, and unregulated products add quality risks [10].

What is the right dose of peptides for muscle growth?

There is no established human dose for this purpose, because no trial has tested these peptides for muscle growth. Questions about approved medicines such as tesamorelin belong with the prescriber and the product label.